Human trials of cancer drug PAC-1 continue with new investment

(University of Illinois at Urbana-Champaign) Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline. The drug was first tested in pet dogs with spontaneously occurring cancers.